biguanides has been researched along with nintedanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, H; Cho, JM; Kim, HJ; Kim, HR; Kim, YS | 1 |
| He, T; Liu, Y; Wang, M; Xu, Y; Yang, M; Yuan, H; Zhang, Y | 1 |
2 other study(ies) available for biguanides and nintedanib
| Article | Year |
|---|---|
The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
Topics: Animals; Biguanides; Bleomycin; Disease Models, Animal; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Pyridones; Republic of Korea | 2019 |
Biguanides decorated albumin nanoparticles loading nintedanib for synergic enhanced hepatocellular carcinoma therapy.
Topics: Biguanides; Carcinoma, Hepatocellular; Humans; Indoles; Liver Neoplasms; Nanoparticles; Serum Albumin, Bovine; Tumor Microenvironment | 2021 |